Treatment outcomes of immune-related cutaneous adverse events
- Phillips, Gregory
- Wu, Jennifer
-
Hellmann, Matthew
- Postow, Michael
- Rizvi, Naiyer
-
Freites Martinez, Azael
- Chan, Donald
-
dusza, stephen1
- Motzer, Robert J.
- Rosenberg, Jonathan E.
- Callahan, Margaret K.
- Chapman, Paul B.
-
Geskin, Larisa
- Lopez, Adriana T
- Ree, Vanessa A.
-
Fabbrocini, Gabriella
-
Annunziata, Maria Carmela
-
Kukoyi, Oluwaseun1
-
Pabani, Aliyah
- Chung, Wen-Hung
-
Markova, Alina1
-
Lacouture, Mario2, 3, 1
Description
PURPOSETheaimofthe current study was to report the efficacy of topical and systemic treatments for immune
related cutaneous adverse events (ircAEs) attributed to checkpoint inhibitors in an uncontrolled cohort of
patients referred to oncodermatology clinics.
METHODS A retrospective analysis of patients with ircAEs evaluated by dermatologists from January 1, 2014, to
December 31, 2017, at three tertiary care hospitals and cancer centers were identified through electronic
medical records. Clinicopathologic characteristics, dermatologic therapy outcome, and laboratory data were
analyzed.
RESULTS A total of 285 patients (median age, 65 years [range, 17 to 89 years]) with 427 ircAEs were included:
pruritus (n = 138; 32%), maculopapular rash (n = 120; 28%), psoriasiform rash (n = 22; 5%), and others (n =
147; 34%). Immune checkpoint inhibitor class was associated with ircAE phenotype (P = .007), where
maculopapular rash was predominant in patients who received combination therapy. Severity of ircAEs was
significantly reduced (mean Common Terminology Criteria for Adverse Events grade: 1.74 v 0.71; P , .001) with
dermatologic interventions, including topical corticosteroids, oral antipruritics, and systemic immunomodu
lators. A total of 88 ircAEs (20%) were managed with systemic immunomodulators. Of these, 22 (25%) of 88
persisted or worsened. In seven patients with corticosteroid-refractory ircAEs, improvement resulted from tar
geted biologic immunomodulatory therapies that included rituximab and dupilumab. Serum interleukin-6 (IL-6)
was elevated in 34 (52%) of 65 patients; grade 3 or greater ircAEs were associated with increased absolute
eosinophils (odds ratio, 4.1; 95% CI, 1.3 to 13.4) and IL-10 (odds ratio, 23.8; 95% CI, 2.1 to 262.5); mean
immunoglobulin E serum levels were greater in higher-grade ircAEs: 1,093 kU/L (grade 3), 245 kU/L (grade 2),
and 112 kU/L (grade 1; P = .043).
CONCLUSION Most ircAEs responded to symptom- and phenotype-directed dermatologic therapies, whereas
biologic therapies were effective in patients with corticosteroid-refractory disease. Increased eosinophils, IL-6,
IL-10, and immunoglobulin E were associated with ircAEs, and they may represent actionable therapeutic
targets for immune-related skin toxicities.
Files
Additional details
Related works
- Cites
- Journal article: 10.1200/JCO.18.02141 (DOI)
References
- DOI: 10.1200/JCO.18.02141